Index Rebal/Special Situations, Quiddity Advisors

Janaghan Jeyakumar, CFA

Index Rebal/Special Situations

Quiddity Advisors

Pan-Asia Catalysts/Events

Index Rebalance

<ul>
<li>ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.</li>
<li>We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.</li>
<li>With approximately 91% of the review period complete, the rankings have largely stabilized.</li>
</ul>


ChiNext and ChiNext 50, respectively, represent the top 100 and top 50 A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
We expect 7 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.
With approximately 91% of the review period complete, the rankings have largely stabilized.


Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Expected ADDs Sharply Down Vs Expected DELs

T&S Communications Co Ltd / Index Rebalance

<ul>
<li>The ChiNext index represents the performance of the 100 largest and most liquid A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.</li>
<li>The ChiNext 50 index is a subset of the ChiNext index and it consists of the top 50 names in the ChiNext index with the highest daily average turnover.</li>
<li>We see 10 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.</li>
</ul>


The ChiNext index represents the performance of the 100 largest and most liquid A-share stocks listed on the ChiNext Market of the Shenzhen Stock Exchange.
The ChiNext 50 index is a subset of the ChiNext index and it consists of the top 50 names in the ChiNext index with the highest daily average turnover.
We see 10 changes for the ChiNext index and 5 changes for the ChiNext 50 index in the next index rebal event.


Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Many Changes; US$2.1bn+ Combined One-Way Flows

HK/China Equity Long-Short

Osbert Tang, CFA

Equity Capital Markets

Cofoe Medical Technology / Equity Capital Markets

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-ltd" target="_blank" data-smartkarma-citation="entities:45716:1" rel="noopener">Cofoe Medical Technology (1187 HK)</a> launched its H-share IPO at HK$39.33, valuing the stock at 16.4x PER for FY26, a discount to the global peers.</li>
<li>Its 3-year EPS CAGR of 18.8% is ahead of the global average, but its market capitalisation of HK$9.3bn is materially smaller.</li>
<li>Using a 10% PER discount to global peers, it has a fair range of HK$41.8-45.2, which equals a reasonable 27-33% discount to its A-share <a href="https://www.smartkarma.com/entities/cofoe-medical-technology-co-lt" target="_blank" data-smartkarma-citation="entities:34791:1" rel="noopener">Cofoe Medical (301087 CH)</a>. </li>
</ul>



Cofoe Medical Technology (1187 HK) launched its H-share IPO at HK$39.33, valuing the stock at 16.4x PER for FY26, a discount to the global peers.
Its 3-year EPS CAGR of 18.8% is ahead of the global average, but its market capitalisation of HK$9.3bn is materially smaller.
Using a 10% PER discount to global peers, it has a fair range of HK$41.8-45.2, which equals a reasonable 27-33% discount to its A-share Cofoe Medical (301087 CH). 


Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>The performance fluctuations of Cofoe in recent years are mainly due to the fade of COVID-19 dividend, excessive dependence on marketing/online channels, and insufficient investment in its own R&amp;D.</li>
<li>Yuyue’s internationalization is more mature as products are more recognized by overseas customers. Yuyue has been able to achieve internationalization through independent branding/OBM, while Cofoe is lagging behind.</li>
<li>The model of "emphasizing marketing over R&amp;D" is hard to last. We think reasonable valuation of Cofoe could be lower than Yuyue and may also be lower than <a href="https://www.smartkarma.com/entities/winner-medical-co-ltd" target="_blank" data-smartkarma-citation="entities:35839:1" rel="noopener">Winner Medical</a>.</li>
</ul>


The performance fluctuations of Cofoe in recent years are mainly due to the fade of COVID-19 dividend, excessive dependence on marketing/online channels, and insufficient investment in its own R&amp;D.
Yuyue’s internationalization is more mature as products are more recognized by overseas customers. Yuyue has been able to achieve internationalization through independent branding/OBM, while Cofoe is lagging behind.
The model of "emphasizing marketing over R&amp;D" is hard to last. We think reasonable valuation of Cofoe could be lower than Yuyue and may also be lower than Winner Medical.


Pre-IPO Cofoe Medical Technology (A/H Listing) - The Business Model and the Concerns Behind

Shanghai Haohai Biological Tec / Index Rebalance

Shanghai Haohai Biological Tec (688366 CH)

<ul>
<li>The June 2025 index review results for the CSI Medical Service Index were announced after market close on Friday 30th May 2025.</li>
<li>There will be 6 changes for the CSI Medical Service index.</li>
<li>We expect one-way flows of approximately US$286mn in the June 2025 index rebal event.</li>
</ul>


The June 2025 index review results for the CSI Medical Service Index were announced after market close on Friday 30th May 2025.
There will be 6 changes for the CSI Medical Service index.
We expect one-way flows of approximately US$286mn in the June 2025 index rebal event.


Quiddity CSI Medical Jun25 Results: 6 ADDs/DELs Confirmed; US$286mn One-Way Flows

China

Winner Medical Co., Ltd. manufactures and distributes health care supplies. The Company produces medical dressings, wound care products, medical protective supplies, disinfection products, operation room infection supplies, and other products. Winner Medical markets its products throughout China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Winner Medical (300888 CH)

Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Expected ADDs Sharply Down Vs Expected DELs

We see US$373mn and US220mn one-way flows for ChiNext and ChiNext 50 respectively. ChiNext expectations are mostly final but ChiNext 50...

Janaghan Jeyakumar, CFA

Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Many Changes; US$2.1bn+ Combined One-Way Flows

Both ChiNext and ChiNext 50 ADDs have strongly outperformed ChiNext and ChiNext 50 DELs on average during the last month. There are multiple months...

Janaghan Jeyakumar, CFA

Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...

Osbert Tang, CFA

Pre-IPO Cofoe Medical Technology (A/H Listing) - The Business Model and the Concerns Behind

Cofoe's performance struggles due to COVID-19 dividend fade. The model of "emphasizing marketing over R&D" is hard to last, which may lead to...

Xinyao (Criss) Wang

Quiddity CSI Medical Jun25 Results: 6 ADDs/DELs Confirmed; US$286mn One-Way Flows

All of our predictions were correct. However, there were some extra changes. We estimate there to be US$286mn in one-way flows in June 2025.

Janaghan Jeyakumar, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Expected ADDs Sharply Down Vs Expected DELs

We see US$373mn and US220mn one-way flows for ChiNext and ChiNext 50 respectively. ChiNext expectations are mostly final but ChiNext 50...

Janaghan Jeyakumar, CFA

Quiddity Leaderboard ChiNext & ChiNext 50 Dec26: Many Changes; US$2.1bn+ Combined One-Way Flows

Both ChiNext and ChiNext 50 ADDs have strongly outperformed ChiNext and ChiNext 50 DELs on average during the last month. There are multiple months...

Janaghan Jeyakumar, CFA

Cofoe Medical Technology (1187 HK) IPO: Priced with Reasonable Potential Gain

​Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...

Osbert Tang, CFA

Pre-IPO Cofoe Medical Technology (A/H Listing) - The Business Model and the Concerns Behind

​Cofoe's performance struggles due to COVID-19 dividend fade. The model of "emphasizing marketing over R&D" is hard to last, which may lead to...

Xinyao (Criss) Wang

Quiddity CSI Medical Jun25 Results: 6 ADDs/DELs Confirmed; US$286mn One-Way Flows

All of our predictions were correct. However, there were some extra changes. We estimate there to be US$286mn in one-way flows in June 2025.

Janaghan Jeyakumar, CFA

Cofoe Medical Technology's H-share IPO values the stock at a discount to global peers. We estimate a fair range of HK$41.8-45.2, balancing the...

Cofoe's performance struggles due to COVID-19 dividend fade. The model of "emphasizing marketing over R&D" is hard to last, which may lead to...